Pharmaceuticals

FDA Approves Altero Biosciences’ Investigational New Drug Application for Treatment of Chemotherapy-Induced Peripheral Neuropathy

bexib
By bexib 0 Min Read

The approval of the ART25.12 New Drug Application will enable Artelo to initiate a Phase 1 trial of the drug for chemotherapy-induced peripheral neuropathy.

You Might Also Like

Kerendia reduces cardiovascular mortality in patients with cardiac, renal and metabolic diseases

Study reveals AI insights can predict disease onset up to 10 years before

Rowing team completes 2,800-mile journey to raise funds for Parkinson’s research

Study finds women treated for ovarian cancer less likely to develop breast cancer

Pharma Pulse 8/30/24: Efforts to expand access and diversity, why “normal” remains a crisis, and more

Share This Article
Previous Article AI Marketing Tools: Automation and Analytics for Better Results (2024)
Next Article $100 Million Crypto Shorts Surge as BTC Surpasses $63,000 – Investorempires.com
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Taiwan emerges as key player in Indian machine tools market with 20.8% growth
Manufacturing
Automobile companies battle AI bots and recruitment competition
Banking
IMTEX, Tooltech & Digital Manufacturing 2025
Manufacturing
“Your money or your life” is defined by Google
Retail & E-commerce